The first FDA-approved CAR-T therapy was tisagenlecleucel, an autologous anti-CD19 CAR-T cell therapy produced by Novartis, which was approved by FDA on August 30, 2017 for the treatment of patients at the age of ≤25 years with B cell precursor acute lymphoblastic leukemia (pre-B ALL) that was refractory or in second or later relapse. Here, CD19 is linked to acute lymphoblastic leukemia.